Liquid Biotech USA, Inc.

A powerful approach to diagnosing cancer at the early stages, with the opportunity of being employed during and post treatment, by detecting live CTCs.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Audubon, PA, US
  • Currency USD
  • Founded November 2015
  • Employees 2
  • Website liquidbiotechusa.com

Company Summary

Our company has developed a non-invasive blood test, a liquid biopsy, to monitor cancer as it develops and is treated during therapy. The advantages of our approach include the ability to take serial biopsies with little risk, isolate live cancer cells and obtain genetic information from those cells that the oncologist can use to direct therapy (personalized medicine).

Team

  • Dr. Philip M. Sass
    Chairman, President, Chief Executive Officer

    Former COO & EVP of Morphotek, Inc., a biotechnology company as well as EVP & Head of Biopharmaceutical Development at Eisai. As co-founder of Morphotek, Inc. obtained $2M in seed funding from Angel investors followed by raising an additional $86M over three venture backed institutional financing rounds, to successfully exit and sell the company to Eisai for $325M.

  • Jeffrey Janco
    COO, EVP, Treasurer, Corporate Secretary & Board Member

    Held senior level managerial positions of Chief Operations Officer, EVP, SVP & Principal Financial Officer at Medical Nutrition USA, Inc., a publicly traded company which engages in the development and distribution of proprietary Nutrition-Medicine products. The Company was acquired by Groupe Danone ("Dannon") in 2010 at which time Mr. Janco assumed additional responsibilities for Nutricia, their Medical Nutrition Division.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free